Myocarditis is a diverse group of heart-specific immune processes classified by clinical and histopathological 
M yocarditis refers to multiple heart-specific inflammatory conditions with a spectrum of clinical and histopathological manifestations (1) . In the late 19th century, the term myocarditis included myocardial infarction and chronic ischemic heart disease. The term has been refined, and presently applies to acute or chronic inflammatory responses of the heart to environmental or endogenous triggers, most commonly viruses, and less frequently bacteria, fungi, and parasites. Important noninfectious causes include giant cell myocarditis (GCM), drug-induced hypersensitivity, and cardiac manifestations of systemic autoimmunity, such as sarcoidosis or systemic lupus erythematosus (2, 3) . This paper seeks to frame recent clinical advances in the management of myocarditis within the latest understanding of pathogenesis from experimental myocarditis models.
The incidence of myocarditis, as ascertained by International Classification of Diseases, 9th Revision diagnoses, was 22 per 100,000 people or approximately 1.5 million cases in the 2013 world population (4) . The burden of myocarditis as a percentage of prevalent heart failure varies by age and region from approximately 0.5% to 4.0% (5) . In 2015, there were approximately 354,000 deaths from myocarditis and cardiomyopathy, with a death rate of 4.8 per 100,000 people ( Figure 1) . Myocarditis is responsible for sudden cardiovascular death in approximately 2% of infant, 5% of childhood, and 5% to 12% of young athlete sudden death (6) . The overall rate of myocarditis was 3% (6 of 200) in autopsies of patients experiencing sudden death in Japan (7) .
Specific forms of myocarditis occur less frequently.
Between October 1998 and December 2014, histologically verified cardiac sarcoidosis (CS) was diagnosed in 233 patients in Helsinki, Finland (8) . The annual detection rate of CS was 0.6 per 100,000 adults (>18 years of age) in the last full 2-year study period between 2013 and 2014. The prevalence of CS in 2012 was 2.2 per 100,000 people. Over the study period, the detection rate of CS increased more than 50-fold. From case series, CS affects 2.3% to 11% of patients with sarcoidosis and 2.5% of unexplained cardiomyopathy in a referral population (diagnosed by heart biopsy, 31 of 1,235). Asymptomatic sarcoid heart involvement is more common. In autopsy studies, myocardial involvement has been seen in 20% to 27% of consecutive sarcoidosis patients (9) .
Also, other granulomatous systemic diseases may involve the heart in a subclinical way. In antinuclear cytoplasmic antibody-associated vasculitis, cardiac involvement is found in up to 65% of patients in remission, the majority caused by nonischemic injury of the heart (10).
GCM is a rare, rapidly progressive, and clinically important form of myocarditis (11) . The estimated annual detection rate for GCM in Finland between 2013
and 2014 was 0.13 per 100,000 people (12, 13) . Over a 23-year period between 1991 and 2015, 55 cases of GCM were diagnosed. The detection rate increased 10-fold over this period. The cause for the increased rate of detection of CS and GCM in Finland is uncertain, and may be related to increased awareness of the diseases, increased referral to an advanced heart failure center, or an increased use of biventricular biopsies over the study timeframe. In autopsy registries, histological evidence of GCM was found in up to 6.6 per 100,000 people or 3% to 5.6% of all myocarditis autopsies (14,15). In endomyocardial biopsy (EMB) studies of dilated cardiomyopathy (DCM) at a tertiary referral center, GCM was found in 0.2% to 1.2%, and 2% of cardiac transplant patients had GCM (16) .
ETIOLOGY
The most commonly identified pathogens in acute myocarditis are viruses (17) . The immune response triggered by injury and autoantigen-specific mechanisms leads to organ dysfunction, pathological remodeling, and heart failure. From the 1950s to the 1990s, enteroviruses were the most frequently identified pathogen, particularly coxsackie virus in North America and Western Europe (18, 19) . In the past 2 decades, polymerase chain reaction and in situ hybridization have identified a range of cardiotropic viruses, including H1N1 strains of influenza (20) , adenovirus Heymans et al. Acute myocarditis results from a variety of injuries that often trigger immune responses to both pathogens and myocardial tissue. Clinical recovery or progression to chronic cardiomyopathy or to recurrent chest pain depends on the balance of regulatory and effector elements.
Chronic injury may be associated with ongoing viral infection.
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New Approaches in Myocarditis 
SEX DIFFERENCES IN MYOCARDITIS AND INFLAMMATORY CARDIOMYOPATHY
Men are diagnosed with myocarditis more often and have a worse prognosis than women, perhaps due to a more pronounced fibrotic response (111) . A key question is whether this difference can lead to sexspecific therapies for acute and chronic myocarditis.
In murine models, male subjects have increased coxsackie B3-induced myocarditis compared with females, due to differences in innate immune responses to coxsackie B3, rather than increased viral replication (112, 113) . MiR-21, -155, -146b, and -590 increase cardiac inflammation and injury in viral and autoimmune myocarditis, whereas the miR-221/222 cluster is protective against both by reducing viral replication and its resulting proinflammatory response. MiR ¼ microRNA.
New Approaches in Myocarditis arrhythmias (147) . Patients with either a PET mismatch or RV involvement had a 3-fold increase in the rate of adverse events. Newer imaging data from CMR and PET should be integrated with established prognostic risk variables, such as QRS width >120 ms, LVEF, and New York Heart Association functional class (147, 148) .
THE ROLE OF EMB
Although EMB is essential for the diagnosis of specific histological disorders, the broad use of EMB as a gold standard has been limited because of cost, availability of experienced centers, and sensitivity 
HOW TO TREAT MYOCARDITIS?
For all patients with myocarditis presenting as heart failure with reduced systolic function, we recommend following the current guidelines and scientific statements for heart failure management.
The current guidelines emphasize gradual titration of neurohormonal-blocking medications, including inhibitors of angiotensin-converting enzyme, angiotensin-receptor blocking agents, and betablockers, to doses used in clinical trials (165, 166) .
Tests for specific causes of myocarditis, such as human 
